Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.1Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 7.81%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive sentiment with significant revenue growth, a successful product portfolio, and strategic FDA approval. While there is an increase in SG&A expenses, the overall performance remains robust, supported by strong financial metrics and promising pipeline developments.Company Guidance
In the call, Xeris Biopharma Holdings, Inc. provided guidance updates and highlighted strong financial performance metrics for the first quarter of 2025. Total revenue grew by 48% year-over-year, reaching $60.1 million, driven by a 41% increase in Recorlev revenue, which exceeded $25 million. The company raised the lower end of its full-year revenue guidance from $255 million to $260 million, indicating an implied full-year total revenue growth of nearly 32% at the midpoint. The gross margin for the quarter was 85%, and the company achieved a positive adjusted EBITDA of $4.4 million. Xeris also noted strategic advancements, such as the FDA approval of Gvoke VialDx and a partnership with American Regent for its commercialization. The company aims to maintain financial discipline, with SG&A and R&D expenses projected to grow in the mid to high single digits, and it plans to remain adjusted EBITDA positive moving forward.Record-Breaking Revenue Growth
Total revenue grew 48% year-over-year to $60.1 million, marking the fourteenth consecutive quarter of over 20% product revenue growth.
Strong Performance of Recorlev
Recorlev net revenue was $25.5 million, up 141% compared to last year, with a 24% increase in the average number of patients.
FDA Approval for Gvoke VialDx
Gvoke VialDx received FDA approval, expanding its use as a diagnostic aid during radiologic examination, in partnership with American Regent.
Positive Adjusted EBITDA
Adjusted EBITDA for the quarter was a positive $4.4 million, supporting the commitment to delivering positive adjusted EBITDA going forward.
Strong Gross Margin
Gross margin in the quarter was 85%, showing a sequential improvement of 200 basis points due to a favorable product mix.
Pipeline Progress with XP-8121
Development of XP-8121 continues to address unmet needs in the hypothyroidism market, with more updates expected at the analyst and investor day.
XERS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
XERS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $4.48 | $5.16 | +15.18% |
Mar 06, 2025 | $3.77 | $4.13 | +9.55% |
Nov 08, 2024 | $3.36 | $3.47 | +3.27% |
Aug 08, 2024 | $2.13 | $2.23 | +4.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Xeris Pharmaceuticals (XERS) report earnings?
Xeris Pharmaceuticals (XERS) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Xeris Pharmaceuticals (XERS) earnings time?
Xeris Pharmaceuticals (XERS) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XERS EPS forecast?
XERS EPS forecast for the fiscal quarter 2025 (Q2) is -0.03.